TMDX Q2 2022 Earnings — TransMedics Group, Inc. Revenue & Financial Results | Market Cap Arena

TMDXTransMedics Group, Inc.

$5B

Q2 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$21M+151.1% YoY

Gross Profit

$14M69.9% margin

Operating Income

-$10M-47.5% margin

Net Income

-$12M-56.2% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+29.2%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$117M

Total Liabilities

$66M

Stockholders' Equity

$51M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$8M	+151.1%
Gross Profit	$14M	$6M	+156.8%
Operating Income	-$10M	-$10M	+1.2%
Net Income	-$12M	-$11M	-8.0%

Revenue Segments

Ocs Liver Product

$10M47%

Ocs Heart Product

$8M39%

Ocs Lung Product

$3M14%

Geographic Segments

UNITED STATES

$18M88%

Non Us And Uk

$2M12%